We're excited to announce Dr. Yoshi Satoh, Vice President of Chemistry at Rev Therapeutics, as one of our Roundtable Facilitators at the Medicinal Chemistry Strategy Meeting West Coast USA 2024 in San Diego on May 22nd! The Roundtable discussion, titled "Pioneering Perspectives and Forward-thinking Approaches in Design and Synthesis for Drug Discovery," promises to be a thought-provoking exploration. Dr. Satoh will delve into the characteristics of ideal chemical templates for efficient optimization, the exciting potential of AI and prediction algorithms in compound design, and strategies to identify high molecular weight compounds with favorable oral bioavailability. Leveraging his deep understanding of drug discovery, Dr. Satoh has a proven track record of guiding molecules from initial concept through clinical trials. Across his work at Novartis and Celgene, he spearheaded the development of numerous drug candidates targeting cardiovascular, inflammatory/immunological, and oncological applications. His expertise spans all facets of the drug discovery process, from structural biology and biochemistry to pharmacology, pharmacokinetics, and even preclinical safety assessments. Don't miss this chance to gain insights from a seasoned expert and explore cutting-edge approaches shaping the future of drug discovery! #MedicinalChemistry #DrugDiscovery #Design #Synthesis #Innovation #SanDiego #EastCoastUSA #RevTherapeutics

We're excited to announce Dr. Yoshi Satoh, Vice President of Chemistry at Rev Therapeutics, as one of our Roundtable Facilitators at the Medicinal Chemistry Strategy Meeting West Coast USA 2024 in San Diego on May 22nd! The Roundtable discussion, titled "Pioneering Perspectives and Forward-thinking Approaches in Design and Synthesis for Drug Discovery," promises to be a thought-provoking exploration. Dr. Satoh will delve into the characteristics of ideal chemical templates for efficient optimization, the exciting potential of AI and prediction algorithms in compound design, and strategies to identify high molecular weight compounds with favorable oral bioavailability. Leveraging his deep understanding of drug discovery, Dr. Satoh has a proven track record of guiding molecules from initial concept through clinical trials. Across his work at Novartis and Celgene, he spearheaded the development of numerous drug candidates targeting cardiovascular, inflammatory/immunological, and oncological applications. His expertise spans all facets of the drug discovery process, from structural biology and biochemistry to pharmacology, pharmacokinetics, and even preclinical safety assessments. Don't miss this chance to gain insights from a seasoned expert and explore cutting-edge approaches shaping the future of drug discovery! #MedicinalChemistry #DrugDiscovery #Design #Synthesis #Innovation #SanDiego #WestCoastUSA #RevTherapeutics

On this last day of #BiophysicsWeek2024, we’re highlighting the small but mighty – fragments!  Fragment-based drug discovery (FBDD) is a key approach that is used to overcome the challenges associated with traditional small molecule drug discovery and to generate lead compounds with improved potency, selectivity, and drug-like properties. Some of these challenges include: Chemical space exploration – small molecules may not efficiently sample the available chemical space, leading to missed opportunities for identifying lead compounds. FBDD focuses on screening fewer, low molecular weight fragments, allowing for more comprehensive sampling of chemical space.  Optimising pharmacokinetic properties – developing lead compounds with favourable pharmacokinetic properties is crucial for drug development. Fragments often have high ligand efficiency, meaning they provide a large contribution to binding affinity per heavy atom.  Selectivity and safety – ensuring the selectivity and safety of lead compounds is essential for minimising off-target interactions and toxicity. Because they are small, fragments can reduce the likelihood of nonspecific interactions and off-target effects. Moreover, FBDD allows for the identification of hits that bind specifically to the target of interest, leading to the design of more selective compounds. Broader target coverage – FBDD is particularly useful for challenging targets (e.g., protein-protein interactions, enzymes with shallow binding pockets) where traditional high-throughput screening may struggle to identify hits. Cost and time constraints  – small molecule drug discovery is resource- and time-intensive. FBDD can help mitigate these challenges by focusing efforts on a smaller set of fragments with higher ligand efficiency, to reduce the number of compounds that need to be synthesised and screened. This can lead to more efficient use of resources and accelerated drug discovery timelines.    Learn more about how our team of expert biophysical scientists and medicinal chemists at Concept Life Sciences have designed and tested our fragment library to identify and optimise novel chemotypes against BRPF1b here . Get in touch with us to discover how we can help you with your FBDD needs! @Malvern Panalytical Pharmaceuticals and @ Biophysical Society #DrugDiscovery #Biophysics #FBDD #HighThroughputScreening #SPR #GCI #SmallMolecules #Fragments #CompChem  #Pharmacokinetics

Certificate in Drug Design and Chemoinformatics | Journal Club | Project In this course, I developed a range of skills, including: - Understanding chemical structures and screening rules - Analyzing the interactions between drugs and receptors - Investigating drug resistance and metabolism - Exploring display formats of pharmaceutical molecules and the fundamental concepts of cheminformatics - Performing molecular similarity calculations - Conducting molecular docking studies - Creating pharmacophore models - Applying QSAR methods "Journal Club" As part of the journal club, I presented a relevant article in cheminformatics titled "Decrypting Orphan GPCR Drug Discovery via Multitask Learning" (https://lnkd.in/dTSwJeZV). I created a PowerPoint presentation to convey the core concepts of the article to my audience. "Project" To validate my skills, I selected a disease and conducted ligand-protein docking studies. I chose to focus on Alzheimer's disease, and I plan to publish the results of this project in the near future. #DrugDesign #Chemoinformatics #JournalClub #pharmacophore #QSAR 2024/8/19

🚨 Call for Papers 🚨 I am serving as a Special Issue Editor for the International Journal of Molecular Sciences MDPI on the topic "Computational Design and Therapeutic Applications of Peptide-Based Drugs." 🧬💻 https://lnkd.in/d5Npg2PF This special issue aims to bring together cutting-edge research and comprehensive reviews on: 🔹 Innovative computational techniques in peptide drug design 🔹 Advances in peptide-based therapeutics 🔹 Novel delivery systems and therapeutic applications 🔹 Emerging trends in peptide engineering and drug discovery We invite researchers from academia and industry to contribute their original research articles and review articles showcasing their latest work in this fast-growing field. 📝 Submission Deadline: 31st March 2025 📄 Submission Link: https://lnkd.in/dNensvVB Join us in advancing the knowledge and application of peptide-based drugs for the future of therapeutics! 🚀 #research #computationalbiology #drugdiscovery #peptidebaseddrugs #therapeutics #molecularscience #MDPI #callforpapers

We are steadfast in our pursuit of valuable collaborations that enhance our existing portfolio and benefit researchers. Our commitment to advancing #nephrologyresearch has led to our latest partnership with Cell4Pharma. As a fellow contract research organization, Cell4Pharma provides cutting-edge nephrology screening assays, offering critical insights into the ADME(T) properties of new compounds. This collaboration, combined with our nephrology platform and team of experts, enables us to offer more comprehensive analysis during your in vitro studies. Below we have included an excerpt from the latest edition of Biotech News and Life Sciences published by Hyphen Projects detailing the collaboration. #PreclinicalCRO #EuropeanCRO #Nephrotoxicity #ADPKD #invitrostudies

At Neuroservices-Alliance, we support biotech and pharmaceutical companies in understanding and enhancing cognitive functions through our advanced Long-Term Potentiation (LTP) assays. 🔎 Using Multi-Electrode Arrays (MEA), we study synaptic plasticity mechanisms crucial for memory and learning processes. Our LTP assays help evaluate the efficacy of compounds on synaptic strength, providing translational data from in vitro models that mimic in vivo conditions. This approach enables precise targeting and optimization of therapeutic interventions for cognitive disorders. Partner with us to accelerate your cognitive drug discovery and development! 🔗 https://lnkd.in/gukXDRAg ✉️ contact@neuroservices-alliance.com #Cognition #MEA #LTP #Synapticplasticity #Drugdiscovery #Drugdevelopment

Here is a practical webinar for a very important class of drug targets.

Hello Dear Connection Exciting News! I am thrilled to announce that my review article, "Recent Trends on Polycaprolactone as a Sustainable Polymer-Based Drug Delivery System in the Treatment of Cancer: Biomedical Applications and Nanomedicine," has been published in the prestigious International Journal of Pharmaceutics (Impact Factor: 5.3), the 3rd most cited journal in Pharmacy and Pharmacology! 🎉 After facing numerous rejections, this publication is incredibly special to me, reflecting my hard work and dedication. A heartfelt thanks to my esteemed guide,Dr Ajazuddin Sir , for his invaluable guidance and support throughout the journey. 🙏 I also want to thank my institution, Rungta College of Pharmaceutical Sciences Kohka-Kurud Road, for providing me with the platform and resources to achieve this milestone. DOI: https://lnkd.in/d2vPZC8M Rejection is not failure; it's a stepping stone to success. To all researchers facing rejection: Don't give up! Keep pushing boundaries! Believe in your work! #RungtaCollege #Pharmacy #Polymer #ResearchPublishing #PerseverancePaysOff #InternationalJournalOfPharmaceutics #Q1Journal #ImpactFactor5point3 #PharmacyAndPharmacology #CancerResearch #Nanomedicine #BiomedicalApplications #Polycaprolactone #DrugDelivery

siRNA therapeutics have gained extensive attention, and to date six siRNAs are approved for clinical use. Despite being investigated in several therapeutic areas, three major "technical" drug development bottlenecks still hold the field back: Targeted accumulation and cellular uptake (entry), endolysosomal escape (escape), and in vivo pharmaceutical performance (efficacy) (three ‘E’ challenges). The current article provides an interesting review of these challenges and promising strategies to overcome them. #sirna #rnatherapeutics #drugdevelopment #drugdelivery